Open AccessHeart Grafts Tolerized Through Third‐Party Multipotent Adult Progenitor Cells Can Be Retransplanted to Secondary Hosts With No Immunosuppression
Author(s) -
Eggenhofer Elke,
Popp Felix C.,
Mendicino Michael,
Silber Paula,
van't Hof Wouter,
Renner Philipp,
Hoogduijn Martin J.,
Pinxteren Jef,
van Rooijen Nico,
Geissler Edward K.,
Deans Robert,
Schlitt Hans J.,
Dahlke Marc H.
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2012-0166
Subject(s) - progenitor cell , immunosuppression , cell therapy , transplantation , population , immunology , multipotent stem cell , cancer research , medicine , mesenchymal stem cell , stem cell , biology , microbiology and biotechnology , pathology , environmental health
This study found that stable allograft survival could be achieved following third‐party multipotent adult progenitor cell (MAPC) infusion in a rat model of fully allogeneic, heterotopic heart transplantation. MAPC‐based immunomodulation represents a promising pathway for clinical immunotherapy and has prompted the initiation of a phase I clinical trial for testing safety and feasibility of third‐party MAPC therapy after liver transplantation.